Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response

Vaccine

Volumn 25, Issue 28, 2007, Pages 5199-5208

  Cheng, Gong ^a   Zhao, Xin ^a   Yan, Weiyao ^a   Wang, Weifeng ^b   Zuo, Xiaopin ^b   Huang, Kai ^b   Liu, Yang ^a   Chen, Jie ^a   Wang, Jialong ^a   Cong, Wei ^a   Liu, Mingqiu ^a   Gao, Huanhe ^b   Chen, Jiulian ^b   Lu, Yonggan ^b   Zheng, Zhaoxin ^a  

^a FUDAN UNIVERSITY   (China)

^b Bio pharmacy   (China)

Author keywords

Foot and mouth disease; Immune response; Interferon; Recombinant protein vaccine

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN G FOOT AND MOUTH DISEASE VIRUS VACCINE; PLASMID VECTOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FOOT AND MOUTH DISEASE VIRUS; IMMUNE RESPONSE; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECOMBINANT PLASMID;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL PROLIFERATION; CYTOKINES; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENE EXPRESSION; IMMUNOGLOBULIN G; INTERFERON-ALPHA; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE; SWINE DISEASES; T-LYMPHOCYTES; VIRAL PROTEINS; VIRAL VACCINES;

EID: 34250172713     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.089     Document Type: Article

References (48)

1. Belsham G.J. Distinctive features of foot-and-disease virus, a member of the picornavirus family-aspects of virus protein-synthesis, protein processing and structure. Prog Biophys Mol Biol 60 (1993) 241-260
2. Pereira H.G. Foot-and-mouth disease. In: Gibbs E.P.J. (Ed). Virus diseases of food animals (1981), Academic Press Inc., London 333-363
3. Barteling S.J., and Vreeswijk J. Developments in foot-and-mouth-disease vaccines. Vaccine 9 (1991) 75-88
4. Baxt B., Morgan D.O., Roberton B.H., and Timpone C.A. Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol 51 (1984) 298-305
5. Collen T., Dimarchi R., and Doel T.R. A T-cell epitope in VP1 of foot-and-mouth-disease virus is immunodominant for vaccinated cattle. J Immunol 146 (1991) 749-755
6. Strohmaier K., Franze R., and Adam K.H. Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol 59 (1982) 295-306
7. Li G.J., Chen W.Z., Yan W.Y., Zhao K., Liu M.Q., Zhang J., et al. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes. Virology 328 (2004) 274-281
8. Liu M.A. Vaccine developments. Nat Med 4 (1998) 515-519
9. Hilleman M.R. Six decades of vaccine development-a personal history. Nat biotechnol 4 (1998) 507-514
10. Cheng G., Chen W.Z., Li Z.F., Yan W.W., Zhao X., Xie J., et al. Characterization of the porcine alpha interferon multigene family. Gene 382 (2006) 28-38
11. Belardelli F. Role of interferons and other cytokines in the regulation of the immune-response. Apmis 103 (1995) 161-179
12. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
13. Braun D., Caramalho I., and Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 14 (2002) 411-419
14. Hunter C.A., Gabriel K.E., Radzanowski T., Neyer L.E., and Remington J.S. Type I interfernons enhance production of IFN-gamma by NK cells. Immunol Lett 59 (1997) 1-5
15. Tough D.F., Borrow P., and Sprent J. Induction of bystander T-cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
16. Marrack P., Kapoler J., and Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 189 (1999) 521-529
17. Nistico P., Tecce P., Giacomini P., Cavallari A., Dagnano I., Fisher P.B., et al. Effect of recombinant human-leukocyte, fibroblast, and immune interferons on expression of class-I and class-II major histocompatibilty complex and invariant chain in early passage human-melanoma cells. Cancer Res 50 (1990) 7422-7429
18. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N.J., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 (1998) 1947-1953
19. Montoya M., Schiavoni G., Mattei F., Gresser I., Belardelli F., Borrow P., et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99 (2002) 3263-3271
20. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191 (2000) 1777-1788
21. Taylor J.L., and Grossberg S.E. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 25 (1998) 23-29
22. Mitani Y., Takaoka A., Kim S.H., Kato Y., Yokachi T., Tanaka N., et al. Cross talk of the interferon-alpha/beta signaling complex with gp130 for effective interleukin-6 signaling. Genes Cells 6 (2001) 631-640
23. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288 (2000) 2357-2360
24. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 10 (1998) 383-390
25. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169 (2002) 375-383
26. Bracci L., Canini I., Puzelli S., Sestili P., Venditti M., Spada M., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 (2005) 2994-3004
27. de Avila Botton S., Brum M.C.S., Bautista E., Koster M., Weiblen R., Golde W.T., et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 24 (2006) 3446-3456
28. Kirby C., and Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 11 (1984) 979-984
29. Golding S.M., Hedger R.S., and Talbot P. Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease. Res Vet Sci 20 (1976) 142-147
30. Chenard G., Miedema K., Moonen P., Schrijver R.S., and Dekker A. A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology. J Virol Methods 107 (2003) 89-98
31. Sun T., Lu P., and Wang X. Localization of infection-related epitopes on the non-structural protein 3ABC of foot-and-mouth disease virus and the application of tandem epitopes. J Virol Methods 119 (2004) 79-86
32. Kang Y.M., Jin H., Zheng G.X., Xie Q.F., Yin J.M., Yu Y., et al. The adjuvant effect of levamisole on killed viral vaccines. Vaccine 23 (2005) 5543-5550
33. Maghni K., Nicolescu O.M., and Martin J.G. Suitability of cell metabolic colorimetric assays for assessment of CD4 + T cell proliferation: comparison to 5-bromo-2-deoxyuridine (BrdU) ELISA. J Immunol Methods 223 (1999) 185-194
34. Barnett P.V., Cox S.J., Aggarwal N., Gerber H., and McCullough K.C. Further studies on the early protective responses in pigs following immunisation with high potency foot-and-mouth disease vaccine. Vaccine 20 (2002) 3197-3208
35. Dozois C.M., Oswald E., Gautier N., Serthelon J.P., Fairbrother J.M., and Oswald I.P. A reverse transcription-polymerase chain reaction method to analyze porcine cytokine gene expression. Vet Immunol Immunopathol 58 (1997) 287-300
36. Choi I.S., Collissoon E.W., Maheswaran S.K., and Yoo H.S. Evaluation of cytokine gene expression in porcine spleen cells, peripheral blood mononuclear cells, and alveolar macrophages by competitive RT-PCR. FEMS Immunolo Med Microbiol 34 (2002) 119-126
37. Isaacs A., and Lindenmann J. Virus interference: the interferon. Proc R Soc Med 147 (1957) 258-267
38. Dalpke A., Zimmermann S., and Heeg K. Immunopharmacology of CpG DNA. Biol Chem 383 (2002) 1491-1500
39. Cox J.C., and Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 15 (1997) 248-256
40. Falcone M., and Sarvetnick N. Cytokines that regulate autoimmune responses. Curr Opin Immunol 11 (1999) 670-676
41. King C., Davies J., Mueller R., Lee M.S., Krahl T., Yeung B., et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 8 (1998) 601-613
42. Mueller R., Bradley L.M., Krahl T., and Sarvetnick N. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 7 (1997) 411-418
43. Morgan H., Bjorn F.L., Michael S.K., Daniel S.C., and Mark M.D. T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 7 (2006) 247-255
44. Lucey D.R., Clerici M., and Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 (1996) 532
45. So E.Y., Park H.H., and Lee C.E. IFN-gamma and IFN-alpha posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol 165 (2000) 5472-5479
46. Chinsangaram J., Koster M., and Grubman M.J. Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J Virol 75 (2001) 5498-5503
47. de los Santos T., Botton S.D., Weiblen R., and Grubman M.J. The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. J Virol 80 (2006) 1906-1914
48. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R.G., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 (1998) 2489-2499